HealthcareLarge capRs 111,776 crRs 112.7 cr traded a dayManufacturingHealthcarePharmaceuticals
Close on 2026-08-21
1,120.00
+1.11%
52-week range75% of the way up
860.601,205.00
Market cap
111,776 cr
P/E (TTM)
25.5×
industry 44×
EPS (TTM)
43.89
Revenue YoY
+29.2%
Q1 FY27
Profit YoY
-33.2%
Net margin
12.4%
-11.5pt vs a year ago
Growth trend
-8.0pt
vs last quarter’s YoY
1 month
+0.6%
Below 52w high
7.6%
RSI (14)
50
Daily swing
2.8%
average true range
Volume
0.7×
vs 20-day average
Traded
Rs 113 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−1.34%
1 month
+0.56%
3 months
+3.80%
6 months
+19.34%
1 year
+12.44%
The read
written from the numbers on this page
The evidence leans constructive7 supporting, 1 against, 1 worth knowing
Supporting
trading 14% above its 200-day average
up 12% over twelve months
matches closed at the day's high, which has beaten the market by +3.19 points over 20 sessions across 2,549 past signals
3 independent kinds of evidence agree today, which is uncommon
revenue grew 29% year on year in the quarter ending 2026-06-30
priced at 26× earnings against an industry median of 44× — 42% below its peers
futures show a long buildup — the move is being funded by new positions
Against
net margin has narrowed from 19.5% to 12.4% across four quarters
Worth knowing
the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
ZYDUSLIFE sits in Manufacturing, Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 980, its 200-day average; open interest reversing while price keeps going.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working2
Revenue rose 53.1% year on year, from Rs 5,237 cr to Rs 8,017 cr.
+53.1%Rs 5,237 crRs 8,017 cr
Net profit rose 7.6% year on year, from Rs 920 cr to Rs 990 cr.
+7.6%Rs 920 crRs 990 cr
Needs watching3
Profit grew slower than revenue, +7.6% against +53.1%.
+7.6%+53.1%
Zydus Lifesciences' net margin fell from 17.6% to 12.4% this quarter versus last year.
17.6%12.4%
Pharmaceuticals is 79% of segment revenue, making it the largest reported segment.
Pharmaceuticals79%
Every figure here is computed from the company’s own filings. Wording of 5 of these 5 lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, measured against zero
What the scans say today
4 of 47 matched on 2026-08-21
ZYDUSLIFE matches 4 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
segments and revenue mix, as the company reports them
ZYDUSLIFE reports 3 business segments. The largest is Pharmaceuticals at 79% of revenue in the quarter ending 2026-06-30. On these numbers this is effectively a single-segment business, so the group result and that segment’s result move together.
SegmentRevenueSharevs a year ago
Pharmaceuticals6,298 cr78.6%—
Consumer products1,436 cr17.9%—
Medical technologies283 cr3.5%—
Segment names are the company’s own, taken verbatim from the reportable-segment disclosure in its quarterly XBRL filing. Nothing on this page describes the business in words we wrote.
Quality of the business
balance sheet as at 2026-03-31
Return on equity
16.2%
trailing profit over shareholders’ funds
Return on capital
14.2%
pre-tax profit over equity plus borrowings
Debt to equity
0.43×
11,770 cr borrowed against 27,111 cr of equity
Net debt
10,914 cr
borrowings less cash
Cash conversion
48%
operating cash flow as a share of profit
Receivable days
71
how long customers take to pay
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 2024-09-06
19×
median 21×
26×
now 26×
ZYDUSLIFE trades at 26× trailing earnings, above its median of 21× over this window — 22% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 29% against the same quarter a year earlier
revenue rose in 4 of the last 4 quarters
Going against it
profit dropped 33% year on year
net margin narrowed from 17.7% to 12.4%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
8,017
1,307
990
9.35
12.4%
Q4 FY26
2026-03-31 · consolidated
7,587
1,660
1,341
12.65
17.7%
Q3 FY26
2025-12-31 · consolidated
6,864
1,353
1,023
10.36
14.9%
Q3 FY25
2024-12-31 · consolidated
5,269
1,184
1,026
10.17
19.5%
Q2 FY25
2024-09-30 · consolidated
5,237
1,271
920
9.06
17.6%
Q1 FY25
2024-06-30 · consolidated
6,208
1,900
1,482
14.11
23.9%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-0.2%
Versus 200-day average+14.2%
Below 52-week high-7.1%
Above 52-week low+30.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)49.8
Higher closes in last 52 of 5
Six-month return+19.34%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.82%
Volume versus 20-day0.7x
Median daily turnoverRs 112.7 cr
Derivatives
near expiry 2026-08-25 · 2026-08-20
Long Buildup
Price up, open interest up. New buyers are arriving rather than old sellers leaving — the move is being funded, not squeezed.
Futures basis versus spot+0.30%
Open interest change+2.5%
Put / call ratio0.63
Put wall (support)1,100
Call wall (resistance)1,180
Max pain1,150
How to read this
Open interest is contracts still open, so a rise means new positions and a fall means positions closing. Combined with price direction that gives the state on the left. The walls are the strikes carrying the most open interest near expiry — levels other people are watching, not levels the price is obliged to respect. A future below spot means sellers are paying to be short.
Peers
Healthcare · 67 classified companies
ZYDUSLIFE trades at 25.5× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 42%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.